https://www.selleckchem.com/products/cddo-im.html
8207±0.0043 0.7799±0.0044). The combined classifier also showed better performance than the tumor feature-based classifier in both training and validation datasets [training dataset 0.791, 95% confidence interval (CI), 0.706-0.860 0.766, 95% CI, 0.679-0.840; validation dataset 0.816, 95% CI, 0.662-0.920 0.766, 95% CI, 0.606-0.885]. Radiomics analysis of combined tumor and non-tumorous bone features showed improved performance of pathological response prediction to chemotherapy in HOS compared to that of tumor features alone. Moreover, t
Like
Comment
Share
